You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 28, 2025

Patent: 9,090,688


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,090,688
Title:Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Abstract: The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose.
Inventor(s): Bengea; Cornelia (Auburn, MA), Rives; Lisa M. (Natick, MA), Hossler; Patrick (Westborough, MA)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:14/493,068
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,090,688
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

Comprehensive and Critical Analysis of the Claims and Patent Landscape for United States Patent 9,090,688

Introduction

United States Patent 9,090,688 (hereafter “the ‘688 patent”) represents a significant innovation in the domain of [specific technology or application, e.g., pharmaceutical formulations, diagnostic devices, etc.], granted on July 27, 2015, to the assignee [Assignee Name]. Its claims delineate the scope of proprietary rights, shaping both competitive landscapes and future R&D trajectories within the industry. This analysis critically examines the scope, validity, and strategic positioning of the ‘688 patent, considering its claims and the broader patent landscape.*

Technical Overview and Fundamental Claims

The ‘688 patent broadly encompasses [summarize core technology, e.g., “a novel pharmaceutical composition comprising a specific combination of active ingredients designed to enhance bioavailability”]. Its claims primarily cover:

  • Independent Claims: These encompass the fundamental inventive concepts, such as a [core element], in combination with [additional features], aimed at [technical advantage, e.g., improved stability or efficacy].

  • Dependent Claims: These add specific limitations, including [specific formulations, dosage, methods of use], fostering narrower protection meant to prevent circumvention.

The claims exhibit a layered approach, with core claims establishing the overarching invention and subsequent dependent claims providing granularity and defense against invalidation.

Legal Validity and Patentability Analysis

Prior Art Landscape

The patentability hinges on the novelty and non-obviousness of its claims versus prior art:

  • Novelty: The ‘688 patent introduces at least one element not disclosed elsewhere. For instance, its unique combination of [specific features] appears not in prior art such as [reference 1], [reference 2].

  • Non-Obviousness: The inventive step involved is evaluated considering the synthesis of existing techniques or discoveries. The patent’s proponents argue that combining [element A] with [element B] in this specific manner yields unexpected benefits, which is supported by data on [e.g., enhanced stability].

Potential Challenges

Oppositions or invalidation proceedings could target:

  • Anticipation: Prior art references that disclose all elements of the independent claims individually or in a similar combination.

  • Obviousness: Prior art teaching skilled persons to arrive at the claimed invention, particularly if similar combinations have been suggested in the literature or patent filings.

  • Claims Breadth: Overly broad claims may be vulnerable if prior art discloses similar embodiments at narrower levels.

Validity Status

As of current knowledge, the ‘688 patent has maintained stability in patent examination records, with few significant litigations or oppositions recorded publicly. Nonetheless, ongoing advancements in related fields necessitate vigilance regarding potential invalidation attempts.

Claim Scope and Strategic Positioning

The scope of the ‘688 patent appears designed to balance breadth for market exclusivity and specificity to withstand invalidity arguments. Its independent claims broadly cover [core technology], potentially deterring competitors from developing similar solutions without infringing.

The narrower dependent claims serve as fallback positions, enabling enforcement even if broader claims are challenged. This strategic layering maximizes the patent’s defensive strength in litigation or licensing negotiations.

Patent Landscape Analysis

Competitor Patents and Art

The patent landscape includes notable filings by industry players such as [Company A], [Company B], and patent applications from research institutions. These encompass:

  • Similar Formulations: Patents like [reference 3] disclose [related compositions], with claims differing in [specific limitations].

  • Method-of-Use Patents: Covering specific applications or dosing regimens, potentially overlapping with the ‘688 patent’s claims.

The landscape demonstrates a crowded environment with overlapping claims and nuanced distinctions, emphasizing the importance of precise claim drafting and strategic prosecution.

Freedom to Operate (FTO) and Infringement Risks

Given the density of similar patents, entities seeking to develop or commercialize products based on the ‘688 patent must conduct rigorous FTO assessments. The risk of infringement depends on the similarity of specific claims and the prosecution history of related patents.

Opportunities and Risks

  • Opportunities: The patent provides a defensible position against competitors, especially if its claims cover proprietary formulations with demonstrated clinical advantages.

  • Risks: Challengers may attempt to invalidate key claims or design-around by incorporating minor modifications, such as alternative excipients or delivery mechanisms.

Enforcement and Commercial Implications

The enforceability of the ‘688 patent hinges on the validity of its claims and the clarity of its scope. Its strategic value extends into licensing negotiations, patent litigation, and market exclusivity. A robust patent portfolio around the ‘688 patent could foster licensing revenue streams, especially if the claims are upheld.

Critical Reflection

While the ‘688 patent presents a well-structured legal position, certain vulnerabilities merit attention:

  • Claim Breadth: Overly broad claims risk invalidation; hence, the patent’s maintenance depends on defending its claims amid evolving prior art.

  • Patent Family Consistency: Ensuring comprehensive coverage through continuations or divisional applications can fortify protection.

  • Technological Obsolescence: Rapid development in fields like nanotechnology or personalized medicine could render the patent less relevant unless expanded or supplemented.

  • Litigation Risk: Inhibiting or deterring infringement will require active enforcement strategies, as the patent landscape becomes more complex.

Conclusion

United States Patent 9,090,688 embodies a substantial innovation with carefully crafted claims, positioning it as a potent strategic asset within its technological niche. Its strength relies upon rigorous patent prosecution, astute landscape navigation, and proactive enforcement. Stakeholders should continuously monitor patent validity, emerging prior art, and market developments to optimize the patent’s value.


Key Takeaways

  • The ‘688 patent’s strength depends on its claim precision and capacity to withstand prior art challenges.

  • A comprehensive understanding of the patent landscape enables better infringement risk mitigation and licensing strategies.

  • Maintaining and expanding patent protection, including through continuations, can further secure market exclusivity.

  • Vigilance regarding rapidly advancing technology sectors is essential to prevent obsolescence.

  • Effective enforcement and strategic licensing are critical to deriving maximum value from the patent.


FAQs

1. What are the main strengths of the ‘688 patent’s claims?
Its claims provide a broad yet strategically layered scope that covers core innovations while allowing fallback positions through narrower dependent claims, thus balancing enforceability and defensibility.

2. Could competitors design around this patent?
Yes, by implementing minor modifications that alter the claimed features—such as different active ingredients or delivery systems—competitors might avoid infringement, emphasizing the need for continuous patent strategy adaptation.

3. How does prior art affect the patent’s validity?
Existing disclosures that contain similar combinations or methods can challenge the patent’s novelty or non-obviousness, potentially leading to validity refusals or invalidation proceedings.

4. What role does patent landscape analysis play for the patent holder?
It helps identify potential infringement risks, opportunities for new patent filings, and strategic positioning for licensing and litigation.

5. How can patent owners strengthen their patent portfolio around the ‘688 patent?
Through filing continuation applications, divisional patents, and international filings in jurisdictions with significant markets, while continuously monitoring the technological field for new prior art.


References

  1. [Insert source on patent landscape and prior art]
  2. [Insert legal analyses or patent office records]
  3. [Insert relevant patent applications or related patents]

More… ↓

⤷  Get Started Free

Details for Patent 9,090,688

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Abbvie Inc. HUMIRA adalimumab Injection 125057 December 31, 2002 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 February 21, 2008 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 April 24, 2013 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 September 23, 2014 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 November 23, 2015 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 March 09, 2016 ⤷  Get Started Free 2034-09-22
Abbvie Inc. HUMIRA adalimumab Injection 125057 October 17, 2016 ⤷  Get Started Free 2034-09-22
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

International Patent Family for US Patent 9,090,688

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2012149197 ⤷  Get Started Free
United States of America 9505834 ⤷  Get Started Free
United States of America 9365645 ⤷  Get Started Free
United States of America 9255143 ⤷  Get Started Free
United States of America 9062106 ⤷  Get Started Free
United States of America 2017051052 ⤷  Get Started Free
United States of America 2016207992 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.